Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.

PURPOSE: Free prostate specific antigen (PSA) in serum consists of heterogeneous molecular subforms. Recently we developed an immunoassay for selective measurement of a subfraction of free PSA called intact PSA, which has been shown to be closely associated with prostate cancer. We assessed the abi...

Full description

Bibliographic Details
Main Authors:	Steuber, T, Nurmikko, P, Haese, A, Pettersson, K, Graefen, M, Hammerer, P, Huland, H, Lilja, H
Format:	Journal article
Language:	English
Published:	2002

Similar Items

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
by: Nurmikko, P, et al.
Published: (2002)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
by: Steuber, T, et al.
Published: (2005)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
by: Haese, A, et al.
Published: (2003)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
by: Haese, A, et al.
Published: (2003)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
by: Haese, A, et al.
Published: (2004)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
by: Piironen, T, et al.
Published: (2006)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Prediction of tumor heterogeneity in localized prostate cancer.
by: Huland, H, et al.
Published: (2002)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
by: Haese, A, et al.
Published: (2000)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
by: Haese, A, et al.
Published: (2003)

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.
by: Nurmikko, P, et al.
Published: (2000)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
by: Haese, A, et al.
Published: (2005)

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
by: Aalamian, M, et al.
Published: (2003)

Circulating biomarkers for prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
by: Bei Xu, et al.
Published: (2021-10-01)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)

Biology of prostate-specific antigen
by: Lilja, H
Published: (2003)

Biology of prostate-specific antigen.
by: Lilja, H
Published: (2003)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues.
by: Cao, Y, et al.
Published: (2003)

A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
by: Valtonen-André, C, et al.
Published: (2007)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
by: Väisänen, V, et al.
Published: (2006)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
by: Siivola, P, et al.
Published: (2000)

Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia
by: Ida Bagus O.W. Putra, et al.
Published: (2016-06-01)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

A massive benign prostate delivered intact: a case report
by: Atif Katib, et al.
Published: (2023-11-01)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
by: Botchorishvili, G, et al.
Published: (2009)

Production of growth factors in benign and malignant prostatic diseases
by: A A Kostin, et al.
Published: (2015-12-01)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
by: Ylikoski, A, et al.
Published: (2001)